Friday, August 25, 2023 2:50:16 PM
REPORT #33 (2023) For Week Ending 8/18/2023.
Thanks once again to @rafunrafun for providing the script data.
The Takeaway Little change in total market (Slide #2), with some slight gains in VASCEPA® vs. generic versions (Slide #5 & Slide #*). Those gains are offset by losses to LOVAZA/Generic (Slide #6 & Slide #7).
Finally, you can see the relative weekly performance changes week/week in Slide #8
You may view the full report for WE 8/18/23 here:
https://drive.google.com/file/d/1tbWudj6uGh4X6g9HjPG3RHZVGexj3xqL/view?usp=sharing
Recent AMRN News
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
